克唑替尼对MET靶点的抑制作用

Crizotinib Exhibits Antitumor Effects on MET

下载PDF

导出

摘要 1文献来源研究一：Zou HY,Li Q.An orally available small-molecule inhibitor of c-Met,PF-2341066,exhibits cytoreductive antitumor efficacy throughantiproliferative and antiangiogenic mechanisms[J].Cancer Res,2007,67（9）：4408-4417.

作者周建英雷源源

机构地区浙江大学医学院附属第一医院呼吸科广东省人民医院肿瘤中心广东省医学科学院广东省肺癌研究所

出处《循证医学》 CSCD 2014年第4期204-208,共5页 The Journal of Evidence-Based Medicine

关键词克唑替尼 MET Crizotinib MET

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met- dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo [J]. Cancer Res, 2003,63(21): 7345-7355.
2Okamoto W, Okamoto I, Arao T, et al. Antitumor action of the MET tyrosine kinase inhibitor Crizotinib (PF-02341066) in gastric cancer positive for MET amplification [J]. Mol Cancer Ther, 2012,11(7) : 1557-1564.
3Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product [J]. Science, 1991,251 (4995) : 802-804.
4Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of Crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification[J ]. J Thorac Oncol, 2011,6(5) : 942-946.
5Efficacy and safety of Crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). Paper presented at: The American Society of Clinical Oncology (ASCO), Chicago, 2014. J Clin Oncol 32:5s, 2014 (suppl; abstr 8001) Available at: http://meetinglibrary.asco.org/ content/132030-144.
6Go H, Jeon YK, Park H J, et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2010,5(3):305-313.
7Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients [J]. J Clin Oncol, 2009,27(10) : 1667-1674.
8Engelman JA, ZejnuUahu K, Mitsudomi T, et al. MET amplification leads to Gefitinib resistance in lung cancer by activating ERBB3 signaling [ J ]. Science, 2007,316 (5827) :1039-1043.
9Chen X, Zhou JY, Zhao J, et al. Crizotinib overcomes hepatoeyte growth factor-mediated resistance to Gefitinib in EGFR-mutant non-small-cell lung cancer cells [J]. Antieaneer Drugs, 2013,24(10) : 1039-1046.

1陆舜,江本元.一种新型的口服c-Met抑制剂PF-2341066可通过抗增殖和抗血管生成两种机制发挥抗肿瘤作用[J].循证医学,2010,10(4):204-206. 被引量：1
2PF-2341066治疗EML4-ALK易位阳性的非小细胞肺癌有临床疗效[J].中国新药杂志,2009,18(18):1689-1690.
3蒲丹,侯梅,李安娜.MET基因突变在肺癌中的种族差异及功能分析[J].循证医学,2014,14(4):216-218.
4黎乐群,林进令,江文枢.肝细胞癌病人肝内转移和术后复发病灶的细胞克隆来源研究[J].中华实验外科杂志,1996,13(3):133-134.
5王长利,李磊,陈志勇.吸烟与肺癌发生的关系[J].循证医学,2009,9(4):206-208. 被引量：11
6Yan-lin WEI,Lei XU,Yun LIANG,Xiao-hua XU, Xiao-ying ZHA.Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo[J].Acta Pharmacologica Sinica,2009,30(4):451-457. 被引量：13
7Xueqin YANG,Li MA,Wen XIAO,Daxing ZHU,Jun CHEN,Zhihao WU,Hongyu LIU,Dong WANG,Zhi HAO,NagalakshmiNADIMINTY,Allen C. GAO,Qinghua ZHOU.The N-Terminal Kinase Suppressor of Ras (KSR1) Complex Exhibits Nucleoside Diphosphate Kinase (NDPK) Activity[J].中国肺癌杂志,2009,12(6):494-496.
8赵仲蓉,李国威,王宝太,李润民,杨增尚,代社教,彭玉萍.肝脏巨大海绵状血管瘤碘油栓塞治疗及其血供研究[J].中华放射学杂志,1994,28(7):472-475. 被引量：100
9步星耀,章翔,张旭,易声禹.人脑肿瘤猴病毒40的感染状况及来源研究[J].中华流行病学杂志,2000,21(1):19-21. 被引量：3
10胡成平,屈晶晶,娄娜娜.MET激酶在非小细胞肺癌中的活化[J].循证医学,2014,14(4):209-212.

循证医学

2014年第4期

浏览历史

内容加载中请稍等...

克唑替尼对MET靶点的抑制作用

参考文献9

相关作者

相关机构

相关主题

浏览历史